HepQuant

HepQuant is a United States-based medical diagnostics company headquartered in Denver, Colorado. The company has developed noninvasive, blood-based, quantitative tests that assess liver health by measuring critical liver cell processes and blood flow to the liver. Its flagship offering, the HepQuant DuO test, delivers a Disease Severity Index (DSI) that assesses a patient's current level of liver impairment and disease state. Results are intended to support healthcare providers' clinical decisions, including whether to defer invasive procedures or to evaluate a patient's risk for clinical complications and disease progression. The company positions its technology as filling a gap in today's diagnostic toolbox, which lacks a quantitative test to assess liver health. HepQuant DuO testing is based on the measurement of cholate uptake by the liver to quantify liver function and portal systemic shunting. Cholate uptake is a natural process specific to the liver. The test harnesses advanced mass spectrometry to measure ultra-low concentrations of molecules accurately. HepQuant states that its products enable healthcare providers to manage patients with liver diseases more effectively and to identify people at risk for developing chronic liver disease. HepQuant's mission is to improve the lives of people with, or at risk for, liver diseases by delivering quantitative, accurate measures of liver health across the full spectrum of disease severity to clinicians, researchers, drug developers, and patients. Its vision is to transform the management of liver disease. The company also offers Pharma Solutions, suggesting it works with pharmaceutical partners, and provides resources for patients and healthcare providers. HepQuant is a private company; no parent company or ownership details are provided in the available evidence.

HepQuant is a medical diagnostics company based in Denver, Colorado, United States. The company was founded to address a gap in liver disease diagnostics: the absence of a quantitative, noninvasive test to assess liver health. HepQuant developed noninvasive, blood-based tests that measure critical liver cell processes and blood flow to the liver. Its flagship product, the HepQuant DuO test, reports a Disease Severity Index (DSI) based on the measurement of cholate uptake by the liver to quantify liver function and portal systemic shunting. The test leverages advanced mass spectrometry to measure ultra-low concentrations of molecules accurately. HepQuant also offers Pharma Solutions, indicating collaboration with pharmaceutical partners. The company's mission is to improve the lives of people with, or at risk for, liver diseases by delivering quantitative, accurate measures of liver health across the full spectrum of disease severity to clinicians, researchers, drug developers, and patients. Its vision is to transform the management of liver disease. As of the available evidence, HepQuant is a private company headquartered in Denver, Colorado.

Noninvasive, blood-based quantitative liver health testing that provides actionable results to inform clinical management of liver disease.

• HepQuant DuO test

  A noninvasive, blood-based test that delivers a Disease Severity Index (DSI) to assess liver impairment and disease state, based on cholate uptake measurement.

• Pharma Solutions

  Services for pharmaceutical partners, likely supporting drug development and clinical trials.

1. 1Home - HEPQuanthepquant.com
2. 2Products & Services Overview - HEPQuanthepquant.com
3. 3The Company - HEPQuanthepquant.com
4. 4HepQuant (United States) - Wikidatawikidata.org